Will the Phase 2 trial "Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance" reach primary completion on or before Jan 30, 2028?

Resolves Yes if ClinicalTrials.gov record NCT05470504 (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)) shows an actual primary completion date on or before Jan 30, 2028. Registered date at generation: Jan 30, 2028.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   Jan 31, 2028, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.